Analysts Set Expectations for Caribou Biosciences, Inc.’s Q1 2024 Earnings (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBUFree Report) – Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for Caribou Biosciences in a research report issued to clients and investors on Wednesday, January 17th. Leerink Partnrs analyst M. Foroohar forecasts that the company will earn ($0.41) per share for the quarter. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.39) per share.

CRBU has been the subject of a number of other research reports. Cantor Fitzgerald started coverage on Caribou Biosciences in a research note on Wednesday, November 8th. They issued a “neutral” rating for the company. Evercore ISI started coverage on Caribou Biosciences in a research note on Tuesday, October 31st. They issued an “outperform” rating and a $13.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Caribou Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $23.57.

Check Out Our Latest Report on Caribou Biosciences

Caribou Biosciences Stock Down 0.8 %

Shares of CRBU stock opened at $5.20 on Thursday. The stock has a fifty day moving average of $5.54 and a 200 day moving average of $5.56. Caribou Biosciences has a 52 week low of $3.44 and a 52 week high of $8.59. The firm has a market capitalization of $459.84 million, a price-to-earnings ratio of -3.47 and a beta of 2.49.

Caribou Biosciences (NASDAQ:CRBUGet Free Report) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.26. Caribou Biosciences had a negative return on equity of 30.33% and a negative net margin of 273.19%. The firm had revenue of $23.66 million during the quarter, compared to analyst estimates of $3.53 million.

Hedge Funds Weigh In On Caribou Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRBU. Deerfield Management Company L.P. Series C purchased a new position in Caribou Biosciences during the third quarter valued at $16,730,000. Avidity Partners Management LP increased its holdings in shares of Caribou Biosciences by 119.3% during the third quarter. Avidity Partners Management LP now owns 6,050,212 shares of the company’s stock valued at $28,920,000 after acquiring an additional 3,291,612 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Caribou Biosciences by 247.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,648,582 shares of the company’s stock worth $12,660,000 after buying an additional 1,886,484 shares in the last quarter. Bank of America Corp DE increased its holdings in Caribou Biosciences by 950.6% in the 4th quarter. Bank of America Corp DE now owns 1,843,902 shares of the company’s stock worth $11,580,000 after buying an additional 1,668,395 shares in the last quarter. Finally, State Street Corp increased its holdings in Caribou Biosciences by 200.3% in the 3rd quarter. State Street Corp now owns 2,395,470 shares of the company’s stock worth $25,272,000 after buying an additional 1,597,870 shares in the last quarter. Hedge funds and other institutional investors own 59.16% of the company’s stock.

Caribou Biosciences Company Profile

(Get Free Report)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.

Read More

Earnings History and Estimates for Caribou Biosciences (NASDAQ:CRBU)

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.